孕期与儿童使用猴痘疫苗的安全性及有效性:活系统评价与荟萃分析
该活系统评价与荟萃分析纳入27项临床研究(1949–2025),涉及1,406,771名儿童/青少年和11,482名孕妇,评估基于痘苗的猴痘/天花疫苗在孕期和儿童中的安全性及有效性。第一代疫苗未增加自然流产、死胎或早产风险,但与先天畸形风险升高相关(RR 1.25,95%CI 1.01–1.54);儿童中严重不良事件罕见,MVA-BN仅引起轻度自限性反应。第三代猴痘疫苗的安全性和有效性证据仍稀缺,亟需高质量前瞻性研究和药物警戒。
要点
- 第一代痘苗疫苗未增加自然流产、死胎或早产风险,但先天畸形风险轻度升高。
- 儿童中严重不良事件罕见,MVA-BN仅引起轻度自限性反应。
- 尚无研究评估孕期疫苗有效性,第三代猴痘疫苗证据稀缺。
核心结论
- 基于痘苗的疫苗在孕期和儿童中总体安全,但第三代猴痘疫苗的安全性和有效性证据仍稀缺。
研究设计与样本
- 活系统评价与荟萃分析,遵循Cochrane、WHO和PRISMA标准,检索至2025年9月。
- 纳入27项临床研究(1949–2025),涉及1,406,771名儿童/青少年(8项研究)和11,482名孕妇(19项研究)。
主要发现
- 第一代疫苗(Lister、Finnish、Dryvax、APSV)未增加自然流产风险(RR 1.02,95%CI 0.70–1.48)。
- 第一代疫苗未增加死胎风险(RR 1.02,95%CI 0.70–1.48)或早产风险(RR 1.08,95%CI 0.78–1.50)。
- 第一代疫苗与先天畸形风险升高相关(RR 1.25,95%CI 1.01–1.54)。
- 儿童中严重不良事件罕见,MVA-BN仅引起轻度自限性反应。
关键数值与推荐
- 第一代疫苗先天畸形风险RR 1.25(95%CI 1.01–1.54)。
- 自然流产和死胎风险RR均为1.02(95%CI 0.70–1.48)。
- 早产风险RR 1.08(95%CI 0.78–1.50)。
临床怎么用
- 孕期和儿童使用基于痘苗的疫苗时,应权衡先天畸形风险与猴痘感染风险。
- 第三代非复制型疫苗(MVA-BN)在儿童中仅引起轻度自限性反应,可作为可选方案。
- 需加强孕期和儿童接种猴痘疫苗后的药物警戒和长期随访。
局限性
- 多数孕期数据来自第一代疫苗,第二代和第三代疫苗证据有限。
- 无研究评估孕期疫苗有效性,儿童有效性数据有限。
- 纳入研究跨1949–2025年,存在异质性和偏倚风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mpox is a re-emerging zoonotic infection caused by an Orthopoxvirus closely related to smallpox. The 2022-23 global outbreak prompted rapid use of vaccinia-based vaccines, historically developed for smallpox and those of the latest generation used for mpox prevention. Assessing their safety and effectiveness in pregnant persons and children is critical to guide policies protecting populations at an elevated risk of severe illness. OBJECTIVE: This study assessed the safety and effectiveness of mpox and historical smallpox vaccines, administered during pregnancy and childhood. METHODS: We conducted a living systematic review and meta-analysis (PROSPERO CRD42024591322/CRD42024586205) following Cochrane, World Health Organization, and Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) standards. We searched biweekly across major databases, trial registries, preprints, and gray literature (inception to September 2025) for studies evaluating the safety and effectiveness of vaccinia-based smallpox vaccines, including historical (first- and second-generation) and modern (third-generation) vaccines, in maternal and pediatric populations. Reviewers independently conducted study selection, data extraction, and risk-of-bias assessment. Meta-analyses employed random-effects models, and results are presented through an interactive dashboard and a living platform. RESULTS: We included 27 clinical studies (1949-2025), involving 1,406,771 children/adolescents (eight studies) and 11,482 pregnant persons (19 studies). Most maternal data came from first-generation vaccines (Lister, Finnish, Dryvax, APSV). These vaccines were not associated with an increased risk of spontaneous abortion (risk ratio [RR] 1.02, 95% confidence interval [CI] 0.70-1.48), stillbirth (RR 1.02, 95% CI 0.70-1.48), or preterm birth (RR 1.08, 95% CI 0.78-1.50), but were linked to a higher risk of congenital anomalies (RR 1.25, 95% CI 1.01-1.54). Fifty-two fetal vaccinia cases were reported globally up to 1978, with none since. Evidence on second- (ACAM2000) and third-generation (MVA-BN) non-replicating vaccines remains limited. In children, serious adverse events were rare, and MVA-BN caused only mild self-limiting reactions. No study assessed vaccine effectiveness in pregnant persons, while limited pediatric data suggested possible protection after post-exposure prophylaxis. CONCLUSIONS: Vaccinia-based vaccines appear generally safe in pregnancy and children. However, evidence on the safety and effectiveness of third-generation mpox vaccines is still scarce. High-quality prospective studies and strengthened pharmacovigilance are urgently needed to inform policy and clinical decision making.
引用
- Ciapponi A, Ballivian J, Berrueta M, et al. Maternal and Pediatric Use of Vaccines for Mpox: A Living Systematic Review and Meta-analysis of Safety and Effectiveness. Drug Saf. 2026. PMID: 41792577. doi:10.1007/s40264-026-01657-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。